319 related articles for article (PubMed ID: 26567863)
1. Drug-eluting stents to prevent stent thrombosis and restenosis.
Im E; Hong MK
Expert Rev Cardiovasc Ther; 2016; 14(1):87-104. PubMed ID: 26567863
[TBL] [Abstract][Full Text] [Related]
2. Stent thrombosis with drug-eluting stents: is the paradigm shifting?
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Genereux P; Branzi A; Stone GW
J Am Coll Cardiol; 2013 Nov; 62(21):1915-1921. PubMed ID: 24036025
[TBL] [Abstract][Full Text] [Related]
3. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
[TBL] [Abstract][Full Text] [Related]
4. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
5. Metallic Limus-Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra-Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial.
Lemos PA; Abizaid AA; Meireles GC; Sarmento-Leite R; Prudente M; Cantarelli M; Dourado AD; Mariani J; Perin MA; Costantini C; Costa RA; Costa JR; Chamie D; Campos CA; Ribeiro E
Cardiovasc Ther; 2015 Dec; 33(6):367-71. PubMed ID: 26352896
[TBL] [Abstract][Full Text] [Related]
6. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
9. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
[TBL] [Abstract][Full Text] [Related]
10. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting stents - what should be improved?
Steffel J; Eberli FR; Lüscher TF; Tanner FC
Ann Med; 2008; 40(4):242-52. PubMed ID: 18428018
[TBL] [Abstract][Full Text] [Related]
12. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
[TBL] [Abstract][Full Text] [Related]
13. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Smits PC; Hofma S; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; Vuillomenet A; Serra A; Nouche RT; den Heijer P; van der Ent M
Lancet; 2013 Feb; 381(9867):651-60. PubMed ID: 23374650
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
[TBL] [Abstract][Full Text] [Related]
15. A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds.
Waksman R
Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e20-e24. PubMed ID: 29281608
[TBL] [Abstract][Full Text] [Related]
16. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial.
Raungaard B; Jensen LO; Tilsted HH; Christiansen EH; Maeng M; Terkelsen CJ; Krusell LR; Kaltoft A; Kristensen SD; Bøtker HE; Thuesen L; Aarøe J; Jensen SE; Villadsen AB; Thayssen P; Veien KT; Hansen KN; Junker A; Madsen M; Ravkilde J; Lassen JF;
Lancet; 2015 Apr; 385(9977):1527-35. PubMed ID: 25601789
[TBL] [Abstract][Full Text] [Related]
17. Coronary stent strut fracture after drug-eluting stent implantation: a newly recognized complication.
Celik T; Iyisoy A; Dogru MT; Isik E
Int J Cardiol; 2009 Feb; 132(1):121-2. PubMed ID: 17692950
[TBL] [Abstract][Full Text] [Related]
18. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
19. From biodegradable polymers to bioresorbable vascular scaffolds: available evidence in the era of new-generation drug-eluting stents.
Magliulo F; Piccolo R; Franzone A; Esposito G; Danzi GB
Minerva Cardioangiol; 2018 Jun; 66(3):246-261. PubMed ID: 29160048
[TBL] [Abstract][Full Text] [Related]
20. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
